SNAP Update and ResourcesActualización y recursos de SNAP
On November 1, 2025, the requirements to receive and apply to the Supplemental Nutrition Assistance Program (SNAP) benefits have changed. To see the new policies to request SNAP benefits, click here and/or call 211 for SNAP assistance. Learn more
El 1 de noviembre de 2025, cambiaron los requisitos para recibir y aplicar para los beneficios del Programa de Asistencia Nutricional Suplementaria (SNAP, por sus siglas en inglés). Para consultar las nuevas políticas para aplicar para los beneficios de SNAP, haz clic aquí o llama al 211 para obtener ayuda de SNAP. Aprende Más
Transportation UpdateActualización de transporte
SafeRide Health (SRH) is the new provider for all NEMT rides to doctor appointments and pharmacy visits.
Depending on your needs, rides may include wheelchair-lift-equipped vehicles, stretcher vans, minivans, or ambulatory vans. Please let SRH know what type of ride you need when scheduling.
SafeRide Health (SRH) es el nuevo proveedor de todos los servicios de transporte médico que no son de emergencia (NEMT, por sus siglas en inglés) hacia consultas médicas y farmacias.
Según tus necesidades, los servicios de transporte pueden incluir vehículos con elevador para sillas de ruedas, camionetas con camilla, minivans o camionetas ambulatorias. Por favor, informa a SRH qué tipo de transporte necesitas al programar tu traslado.
Sarepta Therapeutics Provides Clinical Updates for ELEVIDYS
Date: November 25, 2025
Attention: Providers
Call to action: Texas Children’s Health Plan (TCHP) would like to inform providers that the Health and Human Services Commission (HHSC) has been made aware of several key updates for the drug:
A boxed warning for the risk of acute serious liver injury and acute liver failure
Removal of the non-ambulatory indication from the “Indication and Usage” section of the Prescribing Information
Expanded guidance for prescribers, including a modified pre- and post-infusion oral corticosteroids regimen, and enhanced monitoring recommendations every week for 3 months post-infusion
A new Warnings & Precaution regarding increased susceptibility to serious infections due to immunosuppression
Background: ELEVIDYS (Delandistrogene moxeparvovec-rokl) (HCPCS code J1413) is an adeno-associated virus vector-based gene therapy indicated for the treatment of individuals aged four years or older with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the DMD gene.
Previously posted TCHP communication on this important topic is available by clicking here.
Next step for Providers: Providers should follow the guidance found in this communication and the following link elevidys.com/pi for prescribing information.
